Our Lady's Childrens Hospital
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The Haematology unit at Our Lady's Children’s Hospital is evaluating innovative treatments for bleeding disorders, with a focus on Hemophilia A and Hemophilia B. Current research aims to confirm long‑term safety and tolerability of a novel RNA‑interference therapy.
- Long‑term safety monitoring of emerging clotting factor therapies
- Strategies to manage patients with inhibitory antibodies
- Quality‑of‑life outcomes for individuals with severe bleeding disorders
Findings will help improve disease management and guide future therapeutic options for patients with inherited clotting deficiencies.
Immune System Diseases
In the pediatric arm of the department, investigators study systemic juvenile idiopathic arthritis to define appropriate dosing of an IL‑6 receptor blocker in children and adolescents.
- Pharmacokinetic profiling in the paediatric population
- Dose‑finding to achieve optimal disease control
- Early markers of treatment response and safety
The work supports better control of inflammation and may reduce long‑term joint damage in young patients.
Neoplasms
Researchers at the Dublin site are conducting a comprehensive programme in acute myeloid leukaemia, high‑risk myelodysplastic syndrome and myeloid sarcoma, testing optimal chemotherapy combinations and stem‑cell transplant conditioning.
- Optimization of induction chemotherapy regimens
- Comparative studies of consolidation strategies
- Evaluation of myeloablative versus reduced‑intensity transplant conditioning
Results are expected to refine treatment pathways and enhance cure rates for these aggressive blood cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Our Lady's Childrens Hospital
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Finding Study of Sarilumab in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis | Sanofi-Aventis Recherche & Developpement | Phase II | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Antithrombin Iii Human | 1 | Unknown | 2024-06-03 | 2024-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.